antisense oligonucleotide + placebo
Phase 1Completed 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Progressive Supranuclear Palsy (PSP)
Conditions
Progressive Supranuclear Palsy (PSP)
Trial Timeline
Feb 16, 2021 โ Oct 17, 2024
NCT ID
NCT04539041About antisense oligonucleotide + placebo
antisense oligonucleotide + placebo is a phase 1 stage product being developed by Novartis for Progressive Supranuclear Palsy (PSP). The current trial status is completed. This product is registered under clinical trial identifier NCT04539041. Target conditions include Progressive Supranuclear Palsy (PSP).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04539041 | Phase 1 | Completed |
Competing Products
20 competing products in Progressive Supranuclear Palsy (PSP)